Belpointe Asset Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Belpointe Asset Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,500	Closed	-$1.08K	–	3670
2023 Q1	$1.08K	Hold	2,500	–	–	﹤0.01%	3456
2022 Q4	$2.95K	Buy	+2,500	New	+$4.07K	﹤0.01%	3126

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CGC

Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return

Belpointe Asset Management's GRNA Position: Q2 2023 in Review

Belpointe Asset Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2023, closing a stake of 2,500 shares — an estimated $1.08K sold.

Belpointe Asset Management first reported a position in GRNA in Q4 2022 and held it in 2 quarters. The position peaked at $2.95K in Q4 2022. 48 funds tracked by Wall St. Rank hold GRNA as of Q2 2023.

Belpointe Asset Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 2,500 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2023, an estimated $1.08K.
Belpointe Asset Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $2.95K in Q4 2022.
48 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.